07.11.16
Headquarters: Ingelheim, Germany
twitter.com/Boehringer
www.boehringer-ingelheim.com
Headcount: 47,501
Year Established: 1817
Revenues: $16,167 (+11%)
Net Income: $1,723 (+51%)
R&D: $3,282 (+13%)
TOP SELLING DRUGS
Jumping four spots to 15, this year proved more successful for Boehringer Ingelheim, having overcome market challenges with pricing in the U.S. for its top selling drugs, and winning approval of Praxbind, a much needed reversal agent for Pradaxa, which helped boost sales that were beginning to slip in 2014 due to the potential dangers of internal bleeding.
Having been named one of the most innovative companies worldwide in 2015, this research-driven pharmaceutical company ranked among the 100 leading global innovators named by news agency Thomson Reuters. Key efforts to remain highly competitive included the sale of its generics business, U.S. subsidiary Roxane, and at the end of 2015. Also, Boehringer entered strategic negotiations with Sanofi to trade its consumer health care business for Sanofi’s animal health business. Shortly thereafter, Boehringer made a strategic investment of .5 billion euros to expands its biopharmaceutical production facility in Vienna.
While the company is pursuing biosimilars, we’ll focus on innovative efforts for the sake of space. With looming patent expirations for Boehringer’s bestseller, respiratory drug Spiriva, it won’t be long before new products are needed to replace future lost sales of the $3.9 billion drug. The significant approval of Praxbind in the U.S. and Europe means that Boehringer now has an agent that reverses the anticoagulant effect of Pradaxa, which is Boehringer’s second top seller.
In Boehringer’s prime indication area, respiratory diseases, the company gained key product approvals in several countries: Spiriva Respimat for asthma, Spiolto for chronic-obstructive pulmonary disease (COPD) and OFEV, which is used to treat the rare disease idiopathic pulmonary fibrosis (IPF) and has been shown to slow disease progression. A Phase III study of OFEV (Nintedanib) in people with systemic sclerosis and lung fibrosis is underway.
Further, the FDA approved Gilotrif (afatinib) as a new oral treatment option for patients with squamous cell lung cancer, providing a new second-line treatment option for patients with the second largest sub-type of non-small cell lung cancer (NSCLC), representing about 20-30% of cases. Studies showed significantly improved overall survival and progression-free survival compared to Genentech’s Tarceva (erlotinib). Gilotrif is already approved in more than 60 countries for the treatment of distinct types of EGFR mutation-positive NSCLC.
Additionally, a head-to-head study demonstrated Gilotrif significantly improved clinical outcomes compared to AstraZeneca’s Iressa (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer.
In metabolic diseases, under the Boehringer/Lilly alliance, the FDA approved Synjardy (empagliflozin and metformin hydrochloride) tablets for the treatment of type 2 diabetes. Synjardy is the third product containing empagliflozin to be approved by the FDA, following Jardiance (empagliflozin) and Glyxambi
(empagliflozin/linagliptin). The Synjardy combination uses complementary mechanisms of action to help control blood glucose. Empagliflozin is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial.
Among late stage assets and alliances, Boehringer and AbbVie partnered to develop and commercialize BI 655066, an anti-IL-23 monoclonal antibody in Phase III development for psoriasis. Boehringer’s BI 655066 cleared skin better, faster and for longer than Janssen’s Stelara (ustekinumab) in a Phase II psoriasis trial. The companies are also evaluating the drug’s potential in Crohn’s disease, psoriatic arthritis and asthma.
Boehringer’s third generation EGFR TKI, BI 1482694, received FDA Breakthrough Therapy Designation for the treatment of non-small cell lung cancer and has the potential to become a new treatment option for patients. Phase I/II data showed 62% objective responses in patients, including 46% with confirmed tumor response. A new global Phase II trial is enrolling patients.
Additionally, Boehringer expanded its position in lung cancer obtaining exclusive rights from Hanmi Pharmaceutical to HM61713, a novel 3rd generation EGFR targeted therapy. This new partnership aims to achieve market authorization for HM61713 for patients with EGFR mutation-positive NSCLC by 2017 in the U.S.
Some early stage R&D efforts include collaborations with Inventiva, BioMed X, and The University of Texas MD Anderson Cancer Center. The Inventiva alliance is and example of Boehringer’s focus on external innovation and aims to develop potential new treatments for idiopathic pulmonary fibrosis and other fibrotic diseases. The BioMed X collaboration aims to identify novel approaches for the treatment psychiatric diseases, and the alliance with MD Anderson Cancer Center will explore new medicines to treat pancreatic ductal adenocarcinoma (PDAC).
Lastly, Boehringer exercised its option under the Oxford Bio Alliance, gaining exclusive rights to an oncology target. This is the second option exercised under the companies’ oncology alliance established in 2013. Boehringer appears well positioned to resume steady growth.
twitter.com/Boehringer
www.boehringer-ingelheim.com
Headcount: 47,501
Year Established: 1817
Revenues: $16,167 (+11%)
Net Income: $1,723 (+51%)
R&D: $3,282 (+13%)
TOP SELLING DRUGS
Drug | Indication | 2015 Sales | (+/-%) |
Spiriva | COPD | $3,882 | 10% |
Pradaxa | atrial fibrillation | $1,406 | 7% |
Micardis | hypertension | $1,044 | -12% |
Trajenta | type 2 diabetes | $993 | 43% |
Jumping four spots to 15, this year proved more successful for Boehringer Ingelheim, having overcome market challenges with pricing in the U.S. for its top selling drugs, and winning approval of Praxbind, a much needed reversal agent for Pradaxa, which helped boost sales that were beginning to slip in 2014 due to the potential dangers of internal bleeding.
Having been named one of the most innovative companies worldwide in 2015, this research-driven pharmaceutical company ranked among the 100 leading global innovators named by news agency Thomson Reuters. Key efforts to remain highly competitive included the sale of its generics business, U.S. subsidiary Roxane, and at the end of 2015. Also, Boehringer entered strategic negotiations with Sanofi to trade its consumer health care business for Sanofi’s animal health business. Shortly thereafter, Boehringer made a strategic investment of .5 billion euros to expands its biopharmaceutical production facility in Vienna.
While the company is pursuing biosimilars, we’ll focus on innovative efforts for the sake of space. With looming patent expirations for Boehringer’s bestseller, respiratory drug Spiriva, it won’t be long before new products are needed to replace future lost sales of the $3.9 billion drug. The significant approval of Praxbind in the U.S. and Europe means that Boehringer now has an agent that reverses the anticoagulant effect of Pradaxa, which is Boehringer’s second top seller.
In Boehringer’s prime indication area, respiratory diseases, the company gained key product approvals in several countries: Spiriva Respimat for asthma, Spiolto for chronic-obstructive pulmonary disease (COPD) and OFEV, which is used to treat the rare disease idiopathic pulmonary fibrosis (IPF) and has been shown to slow disease progression. A Phase III study of OFEV (Nintedanib) in people with systemic sclerosis and lung fibrosis is underway.
Further, the FDA approved Gilotrif (afatinib) as a new oral treatment option for patients with squamous cell lung cancer, providing a new second-line treatment option for patients with the second largest sub-type of non-small cell lung cancer (NSCLC), representing about 20-30% of cases. Studies showed significantly improved overall survival and progression-free survival compared to Genentech’s Tarceva (erlotinib). Gilotrif is already approved in more than 60 countries for the treatment of distinct types of EGFR mutation-positive NSCLC.
Additionally, a head-to-head study demonstrated Gilotrif significantly improved clinical outcomes compared to AstraZeneca’s Iressa (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer.
In metabolic diseases, under the Boehringer/Lilly alliance, the FDA approved Synjardy (empagliflozin and metformin hydrochloride) tablets for the treatment of type 2 diabetes. Synjardy is the third product containing empagliflozin to be approved by the FDA, following Jardiance (empagliflozin) and Glyxambi
(empagliflozin/linagliptin). The Synjardy combination uses complementary mechanisms of action to help control blood glucose. Empagliflozin is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial.
Among late stage assets and alliances, Boehringer and AbbVie partnered to develop and commercialize BI 655066, an anti-IL-23 monoclonal antibody in Phase III development for psoriasis. Boehringer’s BI 655066 cleared skin better, faster and for longer than Janssen’s Stelara (ustekinumab) in a Phase II psoriasis trial. The companies are also evaluating the drug’s potential in Crohn’s disease, psoriatic arthritis and asthma.
Boehringer’s third generation EGFR TKI, BI 1482694, received FDA Breakthrough Therapy Designation for the treatment of non-small cell lung cancer and has the potential to become a new treatment option for patients. Phase I/II data showed 62% objective responses in patients, including 46% with confirmed tumor response. A new global Phase II trial is enrolling patients.
Additionally, Boehringer expanded its position in lung cancer obtaining exclusive rights from Hanmi Pharmaceutical to HM61713, a novel 3rd generation EGFR targeted therapy. This new partnership aims to achieve market authorization for HM61713 for patients with EGFR mutation-positive NSCLC by 2017 in the U.S.
Some early stage R&D efforts include collaborations with Inventiva, BioMed X, and The University of Texas MD Anderson Cancer Center. The Inventiva alliance is and example of Boehringer’s focus on external innovation and aims to develop potential new treatments for idiopathic pulmonary fibrosis and other fibrotic diseases. The BioMed X collaboration aims to identify novel approaches for the treatment psychiatric diseases, and the alliance with MD Anderson Cancer Center will explore new medicines to treat pancreatic ductal adenocarcinoma (PDAC).
Lastly, Boehringer exercised its option under the Oxford Bio Alliance, gaining exclusive rights to an oncology target. This is the second option exercised under the companies’ oncology alliance established in 2013. Boehringer appears well positioned to resume steady growth.